Multicentre study of cefiderocol for treatment of Gram-negative bacteria infections in critically ill patients
-
Published:2024-05
Issue:5
Volume:63
Page:107121
-
ISSN:0924-8579
-
Container-title:International Journal of Antimicrobial Agents
-
language:en
-
Short-container-title:International Journal of Antimicrobial Agents
Author:
Balandín Bárbara, Pintado Vicente, Pérez-Pedrero María José, Martínez-Sagasti FernandoORCID, Sancho-González Milagros, Soriano-Cuesta CruzORCID, Gesso Cristina Martín-Dal, Chicot MartaORCID, de Luna Rafael RuizORCID, Asensio-Martín María José, Catalan Mercedes, Díaz-Díaz Juan José, Carbonell Nieves, Iranzo Reyes, Royuela AnaORCID, Ballesteros Daniel
Reference5 articles.
1. Cefiderocol: A review in serious Gram-negative bacterial infections;Syed;Drugs,2021 2. Multicenter study of ceftolozane/tazobactam for treatment of Pseudomonas aeruginosa infections in critically ill patients;Balandin;Int J Antimicrob Agents,2021 3. Cefiderocol versus high-dose, extended-infusion meropenem for the treatment of Gram-negative nosocomial pneumonia (APEKS-NP): a randomised, double-blind, phase 3, non-inferiority trial;Wunderink;Lancet Infect Dis,2021 4. Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen focused, descriptive, phase 3 trial;Basseti;Lancet Infect Dis,2021 5. Infectious diseases society of America guidance on the treatment of antimicrobial resistant Gram-negative infections;Tamma;Clin Infect Dis,2023
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
|
|